Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer

被引：12

作者：

Wakuda, Kazushige ^{[1
]}

Miyawaki, Taichi ^{[1
]}

Miyawaki, Eriko ^{[1
]}

Mamesaya, Nobuaki ^{[1
]}

Kawamura, Takahisa ^{[1
]}

Kobayashi, Haruki ^{[1
]}

Omori, Shota ^{[1
]}

Nakashima, Kazuhisa ^{[1
]}

Ono, Akira ^{[1
]}

Kenmotsu, Hirotsugu ^{[1
]}

Naito, Tateaki ^{[1
]}

Murakami, Haruyasu ^{[1
]}

Mori, Keita ^{[2
]}

Endo, Masahiro ^{[3
]}

Takahashi, Toshiaki ^{[1
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Nagaizumi, Shizuoka, Japan

[2] Shizuoka Canc Ctr, Clin Trial Coordinat Off, Nagaizumi, Shizuoka, Japan

[3] Shizuoka Canc Ctr, Div Diagnost Radiol, Nagaizumi, Shizuoka, Japan

来源：

IN VIVO | 2019年 / 33卷 / 06期

关键词：

Small-cell lung cancer; second-line chemotherapy; sensitive relapse; cisplatin etoposide and irinotecan; platinum rechallenge; TRIAL COMPARING AMRUBICIN; PHASE-III TRIAL; TOPOTECAN; RECHALLENGE;

D O I：

10.21873/invivo.11727

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: To evaluate treatment efficacy of cisplatin, etoposide, and irinotecan combined therapy (PEI), platinum-rechallenge chemotherapy (Pt-Re) and amrubicin monotherapy (AMR) for patients with sensitive relapsed small cell lung cancer (SCLC). Patients and Methods: We defined sensitive relapse as treatment-free interval (TFI) >= 90 days. We retrospectively collected patients' data from medical records between September 2002 and December 2016. Patients with sensitive relapsed SCLC who received second-line chemotherapy were separated into those treated with PEI, with Pt-Re, or with AMR. Results: Seventy-one patients (16 PEI group, 27 Pt-Re group, and 28 AMR group) were assessable for efficacy. No significant differences in patient characteristics were found among the three groups. The median overall survival (MST) was 29.3 months in the PEI group, 24.6 months in the Pt-Re group, and 20.6 months in the AMR group (p=0.042). Conclusion: A significant difference was observed in the overall survival of patients treated with PEI, Pt-Re and AMR and the MST of PEI was the longest.

引用

页码：2229 / 2234

页数：6

共 18 条

[1] Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials [J].

Ardizzoni, Andrea ;

Tiseo, Marcello ;

Boni, Luca .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) :2211-2218

[2] Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer [J].

Ettinger, David S. ;

Jotte, Robert ;

Lorigan, Paul ;

Gupta, Vicram ;

Garbo, Lawrence ;

Alemany, Carlos ;

Conkling, Paul ;

Spigel, David R. ;

Dudek, Arkadiusz Z. ;

Shah, Chirag ;

Salgia, Ravi ;

McNally, Richard ;

Renschler, Markus F. ;

Oliver, Jennifer W. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2598-2603

[3] Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis [J].

Genestreti, Giovenzio ;

Tiseo, Marcello ;

Kenmotsu, Hirotsugu ;

Kazushige, Wakuda ;

Di Battista, Monica ;

Cavallo, Giovanna ;

Carloni, Federica ;

Bongiovanni, Alberto ;

Burgio, Marco Angelo ;

Casanova, Claudia ;

Metro, Giulio ;

Scarpi, Emanuela ;

Korkmaz, Taner ;

Selcuk, Seber ;

Roopa, Kurup ;

Califano, Raffaele .

CLINICAL LUNG CANCER, 2015, 16 (06) :E223-E228

[4] REINDUCTION CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER [J].

GIACCONE, G ;

FERRATI, P ;

DONADIO, M ;

TESTORE, F ;

CALCIATI, A .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11) :1697-1699

[5] Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial [J].

Goto, Koichi ;

Ohe, Yuichiro ;

Shibata, Taro ;

Seto, Takashi ;

Takahashi, Toshiaki ;

Nakagawa, Kazuhiko ;

Tanaka, Hiroshi ;

Takeda, Koji ;

Nishio, Makoto ;

Mori, Kiyoshi ;

Satouchi, Miyako ;

Hida, Toyoaki ;

Yoshimura, Naruo ;

Kozuki, Toshiyuki ;

Imamura, Fumio ;

Kiura, Katsuyuki ;

Okamoto, Hiroaki ;

Sawa, Toshiyuki ;

Tamura, Tomohide .

LANCET ONCOLOGY, 2016, 17 (08) :1147-1157

[6] Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702 [J].

Inoue, Akira ;

Sugawara, Shunichi ;

Maemondo, Makoto ;

Mori, Yoshiaki ;

Oizumi, Satoshi ;

Harada, Masao ;

Taima, Kageaki ;

Morikawa, Naoto ;

Ishida, Takashi ;

Kinoshita, Ichiro ;

Watanabe, Hiroshi ;

Suzuki, Toshiro ;

Nakagawa, Taku ;

Saito, Ryota ;

Nukiwa, Toshihiro .

LUNG CANCER, 2015, 89 (01) :61-65

[7] Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402 [J].

Inoue, Akira ;

Sugawara, Shunichi ;

Yamazaki, Koichi ;

Maemondo, Makoto ;

Suzuki, Toshiro ;

Gomi, Kazunori ;

Takanashi, Shingo ;

Inoue, Chieko ;

Inage, Minoru ;

Yokouchi, Hiroshi ;

Watanabe, Hiroshi ;

Tsukamoto, Toumei ;

Saijo, Yasuo ;

Ishimoto, Osamu ;

Hommura, Fumihiro ;

Nukiwa, Toshihiro .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5401-5406

[8] Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy [J].

Jotte, Robert ;

Conkling, Paul ;

Reynolds, Craig ;

Galsky, Matthew D. ;

Klein, Leonard ;

Fitzgibbons, James F. ;

McNally, Richard ;

Renschler, Markus F. ;

Oliver, Jennifer W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) :287-293

[9] A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901) [J].

Murakami, Haruyasu ;

Yamamoto, Nobuyuki ;

Shibata, Taro ;

Takeda, Koji ;

Ichinose, Yukito ;

Ohe, Yuichiro ;

Yamamoto, Noboru ;

Takeda, Yuichiro ;

Kudoh, Shinzoh ;

Atagi, Shinji ;

Satouchi, Miyako ;

Kiura, Katsuyuki ;

Nogami, Naoyuki ;

Endo, Masahiro ;

Watanabe, Hirokazu ;

Tamura, Tomohide .

LUNG CANCER, 2014, 84 (01) :67-72

[10] Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer [J].

O'Brien, Mary E. R. ;

Ciuleanu, Tudor-Eliade ;

Tsekov, Hristo ;

Shparyk, Yaroslav ;

Cucevia, Branka ;

Juhasz, Gabor ;

Thatcher, Nicholas ;

Ross, Graham A. ;

Dane, Graham C. ;

Crofts, Theresa .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5441-5447

← 1 2 →